
A hot stock, a cooler hand
Liquidia has been on one of those biotech runs that makes your screen look like it spilled espresso on it — up 175% and still somehow finding attention. But while the stock has been sprinting, JW Asset Management quietly headed for the exit on a chunk of its position.
The sale
According to the note, JW Asset Management sold 83,600 shares of Liquidia in the first quarter, worth about $3 million. That doesn’t mean the fund has lost faith in the company; sometimes a sale is just a sale, and sometimes it’s portfolio housekeeping after a monster run.
Why investors should care
For Liquidia shareholders, the headline matters less because of the dollar amount and more because of the signal. When a stock is already up triple digits, any insider or fund trimming tends to get read like a smoke alarm, even if it’s more about rebalancing than panic.
Big picture: the stock’s momentum is still the story here, but this sale is a reminder that even the hottest biotech names can make investors want to lock in gains before the music stops.
